{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-007330","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.843340+00:00","generated_at":"2026-05-16T08:33:47.246122+00:00","sec_items":["3.01","7.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation","bullets":["Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.","Company ineligible for compliance period due to 1-for-5 reverse stock split on Feb 24, 2025.","Warrants also subject to delisting under Nasdaq Listing Rule 5560(a).","Company paid $20,000 hearing fee and appealed, staying suspension pending panel decision.","No assurance the Nasdaq Panel will grant continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-007330","json":"https://secwatch.observer/filing/0001213900-26-007330.json","markdown":"https://secwatch.observer/filing/0001213900-26-007330.md","text":"https://secwatch.observer/filing/0001213900-26-007330.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026007330/0001213900-26-007330-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026007330/ea0273809-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:33:47.246122+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ff1b678ecdb5c4dbb99d476f29bd9273a1edc4d","claim":"60 DEGREES PHARMACEUTICALS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5560(a)).","evidence_excerpt":"January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. As disclosed in the Notice, Nasdaq staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2). While companies are typically afforded a 180-calen","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026007330/0001213900-26-007330-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)(iv), 5560(a)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}